Shionogi has been granted a patent for a method to increase bone density in mammals. The method involves administering a composition that combines Morus, Scutellaria, and Acacia extracts, each enriched with specific flavonoids, blended in a 1.3:1:1 weight ratio. GlobalData’s report on Shionogi gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Shionogi & Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Shionogi, Cancer treatment biomarkers was a key innovation area identified from patents. Shionogi's grant share as of June 2024 was 58%. Grant share is based on the ratio of number of grants to total number of patents.

Bone density enhancement using specific plant extracts

Source: United States Patent and Trademark Office (USPTO). Credit: Shionogi & Co Ltd

The granted patent US12042523B2 outlines a method for increasing bone density in mammals through the administration of a specific composition. This composition consists of a blend of extracts from three plant sources: Morus, Scutellaria, and Acacia, combined in a weight ratio of 1.3:1:1. The Morus extract is derived from Morus alba, the Scutellaria extract from Scutellaria baicalensis, and the Acacia extract from Acacia catechu. The extracts are enriched with various bioactive compounds, including prenylated flavonoids from Morus, free-B-ring flavonoids from Scutellaria, and flavans from Acacia, with specified ranges for their concentrations.

Further claims detail the specific types of flavonoids and flavans that may be included in the composition, such as Albanin G, Kuwanon G, and catechin. The method also allows for the inclusion of glucosamine-type compounds, which may enhance the formulation's efficacy. The patent specifies that the composition can be formulated in various forms, including tablets, capsules, powders, or granules, and may contain acceptable carriers or excipients, ensuring a flexible approach to delivery. Overall, the patent presents a novel approach to addressing bone density issues in mammals through a targeted blend of natural extracts.

To know more about GlobalData’s detailed insights on Shionogi, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies